Takeda Expands Antibody Collaboration With Xoma
This article was originally published in PharmAsia News
Executive Summary
Takeda and Xoma expanded their discovery and development agreement, increasing the number of therapeutic antibody programs and raising Xoma's potential earnings to $230 million, not including royalties, the companies announced Feb. 28